StockData
Immunic, Inc. logo

Immunic, Inc. (IMUX) stock

IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$7.52+0.19 (+2.59%)

Close on Nov 18, 2026Market cap $102.61MP/E –Yield 0.00%

Immunic operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Immunic's operating income for the twelve months ending Jun 30, 2026 was -$117.88M. For fiscal 2025 it was -$103.23M. The highest annual figure on record is -$9.58M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$103.23M–
FY2024Dec 31, 2024-$98.05M–
FY2023Dec 31, 2023-$99.22M–
FY2022Dec 31, 2022-$119.49M–
FY2021Dec 31, 2021-$91.67M–
FY2020Dec 31, 2020-$48.97M–
FY2019Dec 31, 2019-$37.03M–
FY2018Dec 31, 2018-$12.00M–
FY2017Dec 31, 2017-$52.66M–
FY2016Dec 31, 2016-$41.27M–
FY2015Dec 31, 2015-$52.12M–
FY2014Dec 31, 2014-$50.34M–
FY2013Dec 31, 2013-$31.40M–
FY2012Dec 31, 2012-$9.58M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$35.33M–
Q1 FY2026Mar 31, 2026-$33.24M–
Q4 FY2025Dec 31, 2025-$23.33M–
Q3 FY2025Sep 30, 2025-$25.99M–
Q2 FY2025Jun 30, 2025-$27.08M–
Q1 FY2025Mar 31, 2025-$26.83M–
Q4 FY2024Dec 31, 2024-$25.63M–
Q3 FY2024Sep 30, 2024-$25.73M–
Q2 FY2024Jun 30, 2024-$22.81M–
Q1 FY2024Mar 31, 2024-$23.88M–
Q4 FY2023Dec 31, 2023-$23.38M–
Q3 FY2023Sep 30, 2023-$23.57M–
Q2 FY2023Jun 30, 2023-$25.02M–
Q1 FY2023Mar 31, 2023-$27.25M–
Q4 FY2022Dec 31, 2022-$57.33M–
Q3 FY2022Sep 30, 2022-$20.12M–
Q2 FY2022Jun 30, 2022-$20.61M–
Q1 FY2022Mar 31, 2022-$21.44M–
Q4 FY2021Dec 31, 2021-$21.72M–
Q3 FY2021Sep 30, 2021-$18.39M–
Q2 FY2021Jun 30, 2021-$19.17M–
Q1 FY2021Mar 31, 2021-$32.39M–
Q4 FY2020Dec 31, 2020-$14.19M–
Q3 FY2020Sep 30, 2020-$13.55M–
Q2 FY2020Jun 30, 2020-$12.22M–
Q1 FY2020Mar 31, 2020-$9.01M–
Q4 FY2019Dec 31, 2019-$8.19M–
Q3 FY2019Sep 30, 2019-$9.18M–
Q2 FY2019Jun 30, 2019-$15.01M–
Q1 FY2019Mar 31, 2019-$4.66M–
Q4 FY2018Dec 31, 2018-$5.24M–
Q3 FY2018Sep 30, 2018-$1.81M–
Q2 FY2018Jun 30, 2018-$2.67M–
Q1 FY2018Mar 31, 2018-$14.49M–
Q4 FY2017Dec 31, 2017-$14.78M–
Q3 FY2017Sep 30, 2017-$12.64M–
Q2 FY2017Jun 30, 2017-$12.55M–
Q1 FY2017Mar 31, 2017-$12.69M–
Q4 FY2016Dec 31, 2016-$11.83M–
Q3 FY2016Sep 30, 2016-$10.24M–

More Immunic figures

See a number that looks wrong?